Product logins

Find logins to all Clarivate products below.


Type 2 Diabetes (Fixed-Dose Combinations) | DecisionBase | US | 2014

Are Emerging Fixed-Dose Combinations Poised to Fill the Unmet Need for Drugs with Greater Efficacy?

Type 2 diabetes is a major public health concern, affecting more than 30 million people in the United States alone. A newly diagnosed type 2 diabetic is usually prescribed metformin and lifestyle modification, but as the disease progresses, these patients will be prescribed either additional oral antidiabetic agents or insulin therapy. Because type 2 diabetes patients often take multiple pills for their condition as well as other comorbidities, physicians see fixed-dose combinations (FDCs) as a way to improve convenience and patients’ compliance if they already have a high pill burden. In this report we compare current FDCs used to treat type 2 diabetes and explore which FDCs in development will help to meet the unmet needs identified by physicians and payers.

Related Market Assessment Reports

Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
Report
Obesity – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity (US)
GLP-1 RA products have set new standards for weight-loss drugs and are driving the rapid growth of the obesity market. Novo Nordisk’s semaglutide (Wegovy) and Eli Lilly’s tirzepatide (Zepbound…